Patents by Inventor Adrian Ion Bot

Adrian Ion Bot has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8703142
    Abstract: Embodiments of the invention disclosed herein relate to methods and compositions for bypassing the involvement of CD4+ cells when generating antibody and MHC class I-restricted immune responses, controlling the nature and magnitude of the response, and promoting effective immunologic intervention in viral pathogenesis. More specifically, embodiments relate to immunogenic compositions for vaccination particularly therapeutic vaccination, against HIV and other microbial pathogens that impact functioning of the immune system, their nature, and the order, timing, and route of administration by which they are effectively used.
    Type: Grant
    Filed: December 29, 2005
    Date of Patent: April 22, 2014
    Assignee: Mannkind Corporation
    Inventors: David C. Diamond, Adrian Ion Bot
  • Patent number: 8674081
    Abstract: The present invention provides a method of treating cancer by providing to a subject in need thereof an immunogenic composition comprising a nucleic acid construct encoding a polypeptide comprising CTL epitopes PSMA288-297 and PRAME425-433, or a cross-reactive analogue. In embodiments of the present invention there is provided methods and compositions for inducing, entraining, and/or amplifying the immune response to MHC class-I restricted epitopes of carcinoma antigens to generate an effective anti-cancer immune response.
    Type: Grant
    Filed: July 8, 2011
    Date of Patent: March 18, 2014
    Assignee: Mankind Corporation
    Inventors: Zhiyong Qiu, Adrian Ion Bot
  • Patent number: 8653237
    Abstract: Some embodiments relate to analogs of peptides corresponding to class I MHC-restricted T cell epitopes and methods for their generation. These analogs can contain amino acid substitutions at residues that directly interact with MHC molecules, and can confer improved, modified or useful immunologic properties. Additionally, classes of analogs, in which the various substitutions comprise the non-standard residues norleucine and/or norvaline, are disclosed.
    Type: Grant
    Filed: May 25, 2012
    Date of Patent: February 18, 2014
    Assignee: MannKind Corporation
    Inventors: Liping Liu, Adrian Ion Bot, David C. Diamond
  • Publication number: 20130017213
    Abstract: Some embodiments relate to analogs of peptides corresponding to class I MHC-restricted T cell epitopes and methods for their generation. These analogs can contain amino acid substitutions at residues that directly interact with MHC molecules, and can confer improved, modified or useful immunologic properties. Additionally, classes of analogs, in which the various substitutions comprise the non-standard residues norleucine and/or norvaline, are disclosed.
    Type: Application
    Filed: May 25, 2012
    Publication date: January 17, 2013
    Applicant: MANNKIND CORPORATION
    Inventors: Liping LIU, Adrian Ion BOT, David C. DIAMOND
  • Publication number: 20120148613
    Abstract: The present invention provides a method of treating a cell proliferative disease such as cancer by providing to a subject in need thereof an immunogenic composition comprising plasmid and peptide(s) or analogues thereof. In embodiments of the present invention there is provided methods and compositions for inducing, entraining, and/or amplifying the immune response to MHC class-I restricted epitopes of carcinoma antigens to generate an effective anti-cancer immune response.
    Type: Application
    Filed: December 23, 2011
    Publication date: June 14, 2012
    Applicant: MannKind Corporation
    Inventors: Adrian Ion Bot, Chih-Sheng Chiang, David C. Diamond, Jian Gong, Kent Andrew Smith, Liping Liu, Xiping Liu, Zhiyong Qiu
  • Patent number: 8084592
    Abstract: The present invention provides a method of treating a cell proliferative disease such as cancer by providing to a subject in need thereof an immunogenic composition comprising plasmid and peptide(s) or analogues thereof. In embodiments of the present invention there is provided methods and compositions for inducing, entraining, and/or amplifying the immune response to MHC class-I restricted epitopes of carcinoma antigens to generate an effective anti-cancer immune response.
    Type: Grant
    Filed: June 16, 2006
    Date of Patent: December 27, 2011
    Assignee: MannKind Corporation
    Inventors: Adrian Ion Bot, Chih-Sheng Chiang, David C. Diamond, Jian Gong, Kent Andrew Smith, Liping Liu, Xiping Liu, Zhiyong Qiu
  • Publication number: 20110274723
    Abstract: The instant disclosure relates to methods for treating a cancer patient with an active immunotherapeutic, wherein the methods include assessing a patient's pre-existing immunoreactivity to at least one target antigen, choosing an immunotherapeutic regimen based on the level of pre-existing immunoreactivity, and administering an active immunotherapeutic according to the regimen.
    Type: Application
    Filed: October 22, 2010
    Publication date: November 10, 2011
    Applicant: MANNKIND CORPORATION
    Inventors: Adrian Ion Bot, Zhiyong Qiu, David C. Diamond, Mihail Obrocea
  • Publication number: 20110269949
    Abstract: The present invention provides a method of treating cancer by providing to a subject in need thereof an immunogenic composition comprising a nucleic acid construct encoding a polypeptide comprising CTL epitopes PSMA288-297 and PRAME425-433, or a cross-reactive analogue. In embodiments of the present invention there is provided methods and compositions for inducing, entraining, and/or amplifying the immune response to MHC class-I restricted epitopes of carcinoma antigens to generate an effective anti-cancer immune response.
    Type: Application
    Filed: July 8, 2011
    Publication date: November 3, 2011
    Applicant: MANNKIND CORPORATION
    Inventors: Zhiyong Qiu, Adrian Ion Bot
  • Publication number: 20110230548
    Abstract: Embodiments of the present invention relate to multicistronic vectors and methods for their design. Methods and compositions of the invention include a vector including at least two cistrons, wherein a first cistron includes a first promoter and a first nucleic acid sequence encoding one or more therapeutic agents, and wherein a second cistron comprises a second promoter and a second nucleic acid sequence encoding one or more RNA molecules that interfere with the expression of a biological response modifier or the therapeutic agent, wherein the expression of the first sequence is under control of the first promoter and expression of the second sequence is under control of the second promoter.
    Type: Application
    Filed: February 22, 2011
    Publication date: September 22, 2011
    Applicant: MANNKIND CORPORATION
    Inventors: Adrian Ion Bot, David C. Diamond, Zhiyong Qiu
  • Patent number: 7999088
    Abstract: The present invention provides a method of treating cancer by providing to a subject in need thereof an immunogenic composition comprising a nucleic acid construct encoding a polypeptide comprising CTL epitopes PSMA288-297 and PRAME425-433, or a cross-reactive analogue. In embodiments of the present invention there is provided methods and compositions for inducing, entraining, and/or amplifying the immune response to MHC class-I restricted epitopes of carcinoma antigens to generate an effective anti-cancer immune response.
    Type: Grant
    Filed: June 16, 2006
    Date of Patent: August 16, 2011
    Assignee: MannKind Corporation
    Inventors: Zhiyong Qiu, Adrian Ion Bot
  • Publication number: 20090148478
    Abstract: Disclosed herein are methods and compositions for inducing an immune response against various combinations of tumor-associated antigens, which can promote effective immunologic intervention in pathogenic processes. Embodiments of the invention disclosed herein are directed to the use of effective combinations of TuAAs for the immunotherapy of patients with various types of cancer. Both immunogenic compositions for inducing an immune response to these combinations of antigens and methods for their use are disclosed.
    Type: Application
    Filed: October 16, 2008
    Publication date: June 11, 2009
    Applicant: MANNKIND CORPORATION
    Inventors: Chih-Sheng CHIANG, Adrian Ion BOT, John J.L. SIMARD, David C. DIAMOND
  • Publication number: 20090131355
    Abstract: Embodiments of the present invention relate to multicistronic vectors and methods for their design. Methods and compositions of the invention include a vector including at least two cistrons, wherein a first cistron includes a first promoter and a first nucleic acid sequence encoding one or more therapeutic agents, and wherein a second cistron comprises a second promoter and a second nucleic acid sequence encoding one or more RNA molecules that interfere with the expression of a biological response modifier or the therapeutic agent, wherein the expression of the first sequence is under control of the first promoter and expression of the second sequence is under control of the second promoter.
    Type: Application
    Filed: May 23, 2008
    Publication date: May 21, 2009
    Inventors: Adrian Ion Bot, David C. Diamond, Zhiyong Qiu
  • Publication number: 20080124352
    Abstract: Embodiments of the invention disclosed herein relate to methods and compositions for bypassing the involvement of CD4+ cells when generating antibody and MHC class I-restricted immune responses, controlling the nature and magnitude of the response, and promoting effective immunologic intervention in viral pathogenesis. More specifically, embodiments relate to immunogenic compositions for vaccination particularly therapeutic vaccination, against HIV and other microbial pathogens that impact functioning of the immune system, their nature, and the order, timing, and route of administration by which they are effectively used.
    Type: Application
    Filed: December 29, 2005
    Publication date: May 29, 2008
    Inventors: David C. Diamond, Adrian Ion Bot